Background. Despite a significant increase in fungal blood stream (BSI) infections in India, there is paucity of data on regional prevalence of major fungal species, and risk factors for this infection. We describe the epidemiology and predictors of fungal BSI in a tertiary care center in Kerala, India with a novel antimicrobial stewardship program in place.
Background. While antibiotics frequently cause adverse drug reactions (ADR), the rate of antifungal (AF) ADR is unknown. The mechanisms of AF ADR and cross-reactivity among a drug class (i.e., azoles) are poorly understood. Given the use of AF therapy is on the rise, it is important to better understand the prevalence of AF ADR and how these reactions influence prescribing.
Methods. Thirty-two hospitals participated in a quarterly pediatric point prevalence survey that documented details on all admitted patients 0-17 years receiving any systemic antimicrobials, including drug, dose, and documented history of an antimicrobial ADR between June 2016 and December 2017. Patients who were recorded as receiving at least one systemic AF were included. A comparison of AF prescribing practices between those with and without an AF ADR was performed.
Results. Among 13,179 total patients, 2,213 AF were prescribed to 2,101 unique patients. The most common indications for AF included prophylaxis (64%), fever with neutropenia (4%), neonatal sepsis (3%), and catheter-related bloodstream infection (3%). The prevalence of patients with any documented AF ADR was 2.9%. Amphotericin was most commonly associated with an ADR. Fluconazole was the most commonly prescribed AF in those with no ADR (49%) when compared with those with an AF ADR (13%; P < .05). Patients with an amphotericin ADR were more likely to receive voriconazole (29%) when compared with those without (15%; P < .05). Interestingly, posaconazole use was highest in those with an azole ADR (22%) when compared with those with no azole ADR (4%; P < .05). Echinocandin ADR were infrequent, and those with a reported ADR still received an echinocandin 62% of the time.
Conclusion. Significant differences in antifungal prescribing exists based on ADR status. More work is needed to be able to effectively classify AF ADR, determine safe prescribing practices in those with an AF ADR, and evaluate outcomes associated with AF ADR status. Background. Oral posaconazole (PCZ) is widely used for both prophylaxis and treatment of invasive fungal infections (IFIs) in adult leukemia patients due to its broad antifungal spectrum. However, issues with PCZ tolerability can result in treatment interruption or discontinuation, and the need for alternative oral options with comparable antifungal coverage. Isavuconazole (ISA) is the newest triazole antifungal with a similar spectrum of activity to PCZ and is increasingly used in leukemia patients. Real-world data regarding the tolerability of ISA after PCZ toxicity are lacking.
Methods. We retrospectively assessed safety and tolerability of ISA utilization after PCZ toxicity in adult (age > 18 years) leukemia patients from March 2015 to December 2016. We included all patients who received ≥7 days of oral or intravenous ISA 372 mg immediately after receiving at least one dose of oral PCZ. Demographic and clinical data were recorded including age, sex, underlying disease and disease status, and prior allogeneic stem-cell transplantation (alloSCT). Relevant toxicity markers were collected at three time points: prior to PCZ initiation, at switch to ISA therapy, and after ISA therapy was completed.
Results. We identified 8 such patients, all with acute myeloid leukemia. No patient had prior alloSCT and all except one patient had relapsed or refractory disease (88%). Five patients were neutropenic at the time of ISA initiation. PCZ was administered as prophylaxis in one and as treatment in seven patients. Increased liver function tests (LFTs) or total bilirubin was noted in seven patients on PCZ, while two patients had confirmed Grade 3/4 QTc prolongation. No patient discontinued subsequent ISA due to toxicity. Overall, Grade 3/4 elevations in LFTs were decreased after changing to ISA (25% after PCZ vs. 0% after ISA). The two patients who experienced Grade 3/4 QTc prolongation with PCZ returned to normal EKG findings after changing to ISA.
Conclusion. Overall, we found ISA to be well tolerated in patients requiring discontinuation of PCZ due to toxicity, with no patients discontinuing ISA due to toxicity. ISA was found to be a safe alternative choice in the setting of PCZ toxicity in heavily immunocompromised patients. 
